CTXRCitius Pharmaceuticals, Inc.同业对比
Citius Pharmaceuticals, Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTXR本股 | $15M#5 | — | 0.2x#1 | 169.7x#7 | 0.0%#2 | -0.8%#7 | -42806.2%#7 | -59.7%#2 | — | — | -64.3%#4 | — |
| KYNB | $18M#1 | 0.1x#2 | — | 2.8x#2 | -78.3%#5 | 485.6%#1 | -712.7%#4 | — | — | — | -58.2%#3 | — |
| ELAB | $18M#2 | — | 1.1x#2 | 29.9x#5 | — | -24.0%#10 | -1304.4%#5 | -46.3%#1 | — | — | — | — |
| REVB | $16M#3 | 0.1x#3 | 1.6x#5 | — | — | 40.7%#4 | — | -88.5%#3 | — | — | -88.5%#6 | — |
| MRKR | $16M#4 | — | 1.3x#3 | 4.4x#3 | -46.2%#3 | -13.3%#9 | -363.5%#2 | -100.0%#4 | -1413.6%#2 | — | -6.4%#1 | — |
| ANEB | $15M#6 | — | 1.9x#6 | — | — | -3.5%#8 | — | -106.9%#5 | — | — | -86.2%#5 | — |
| MTNB | $15M#7 | — | 8.1x#10 | 13.3x#4 | -65.6%#4 | 57.3%#2 | -635.0%#3 | -574.7%#10 | — | — | — | — |
| AEON | $15M#8 | — | — | — | — | -193.4%#13 | — | — | — | — | — | — |
| ALLR | $14M#9 | 0.0x#1 | 3.9x#9 | 42.6x#6 | — | 54.2%#3 | -3939.1%#6 | -317.6%#9 | — | — | -40.9%#2 | — |
| ADIL | $13M#10 | — | — | — | — | 39.5%#6 | — | — | — | — | — | — |
| RKTO | $13M#11 | — | 1.6x#4 | — | — | -52.3%#11 | — | -152.0%#7 | — | — | — | — |
| BFRI | $13M#12 | — | 2.1x#7 | 0.3x#1 | 11.7%#1 | 40.7%#5 | -27.2%#1 | -176.9%#8 | -712.4%#1 | — | — | — |
| KAPA | $13M#13 | — | 3.0x#8 | — | — | -109.3%#12 | — | -130.0%#6 | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-02。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议